Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021 2022-03-29
Date of Board Meeting 2022-03-11
VOLUNTARY ANNOUNCEMENT - PRELIMINARY RESULTS OF PHASE II CLINICAL TRIAL OF KN046 IN COMBINATION WITH KN026 FOR THE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HER2-POSITIVE SOLID CANCER ACCEPTED FOR E-POSTER PRESENTATION AT 2022 AACR ANNUAL MEETING 2022-03-09
Next Day Disclosure Return 2022-03-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022 2022-03-03
VOLUNTARY ANNOUNCEMENT - IND APPROVALS BY NMPA FOR A PHASE IA/IB CLINICAL TRIAL OF KN052 IN THE TREATMENT OF ADVANCED SOLID TUMORS AND A PHASE II CLINICAL TRIAL OF KN046 IN COMBINATION WITH AXITINIB IN THE TREATMENT OF ADVANCED NSCLC 2022-02-10
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE III CLINICAL TRIAL OF KN046 FOR THE TREATMENT OF ADVANCED PDAC 2022-02-09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022 2022-02-08
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME 2022-01-27
CONTINUING CONNECTED TRANSACTION ANNOUNCEMENT - RENEWAL OF THE MASTER TECHNICAL SERVICE AGREEMENT 2022-01-14

13 14 15 16 17 18 19